ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
ImmunityBio Inc

ImmunityBio Inc (IBRX)

2.57
0.01
(0.39%)
마감 03 1월 6:00AM
2.6091
0.0391
(1.52%)
시간외 거래: 9:53AM

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

IBRX 뉴스

공식 뉴스 전용

IBRX Discussion

게시물 보기
westjtter westjtter 10 시간 전
Here is how I see it…anything under $3 is a real bargain……I see the stock going up at least 20% in the coming months…so you could buy this thing just for a trade ! However i believe it is going a lot higher…the fact that PSS only raised $100 mil, indicates that management believes there is a big jump in revenue coming in 2025, and there will be plenty of news to support the stock price! We will see!
👍️ 1 😁 1
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 2 일 전
Should climb over $3 as offering closed at $3
Bankers begin support and tax loss selling ends today
January effect should be good
👍️0
Monksdream Monksdream 2 주 전
IBRX under $3
👍️0
westjtter westjtter 2 주 전
Anyone know if the $100 million in stock offering(33 mil shares) is now complete? This was originally to close around Dec 12th....also there was an option for an additional 5 million shares to the underwriters for 30 more days after closing.

Just curious as to who were the buyers of this stock? I would hope and think once this offering closes the share price should slowly start to head higher again.
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 3 주 전
Sub $2.50 next week?
Year-end selling killing this one...or is it something else?
👍️0
jondoeuk jondoeuk 1 월 전
This will be interesting, but we know that cancer cells are able to develop multiple mechanisms that enable the evasion of NKs. These mechanisms are likely the reason why NK based therapies show only limited success in clinic trials. Here is just one mechanism (that was recently found) https://www.cell.com/cell/abstract/S0092-8674(24)00355-6

https://x.com/DrPatSoonShiong/status/1861433583186932141
👍️0
jondoeuk jondoeuk 1 월 전
A new paper on anti-HER2 CAR-NKs (+/- anti-PD-1) https://academic.oup.com/neuro-oncology/article/26/Supplement_8/viii85/7890050
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 2 월 전
what do you think is the biggest factor for the recent rise?
👍️0
glenn1919 glenn1919 2 월 전
IBRX........................https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 2 월 전
IBRX ROCKET SHIP
👍️0
TrendTrade2016 TrendTrade2016 2 월 전
IBRX PUSH PUSH PUSH
👍️0
glenn1919 glenn1919 2 월 전
IBRX...................................https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 2 월 전
IBRX BIO BEAST
👍️0
tw0122 tw0122 2 월 전
Not bad $5.13 + 28%
👍️0
jondoeuk jondoeuk 3 월 전
A case report. From it: ''Here, we report the compassionate use treatment of this combination in a patient with recurrent, metastatic pancreatic cancer (mPC) after 3 lines of therapy. Under the initial single-patient Investigational New Drug (spIND) protocol, the patient received N-803, PD-L1 t-haNK cells, and the albumin doxorubicin conjugate aldoxorubicin for ~27 months. The patient's disease became stable on this regimen, and a transient complete response was observed by ~14 months of therapy. Due to progression, a second spIND protocol was designed whereby the patient received E-EDV-D682 plus EDV-GC for more than 24 months, which resulted in stable disease and the patient's continued survival at the time this report was written.'' https://academic.oup.com/oncolo/advance-article/doi/10.1093/oncolo/oyae267/7814737
👍️ 2
aBeezlee aBeezlee 3 월 전
$2 would be great. We'll see.
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 3 월 전
Wait until it hits $2.50

Hold!
👍️0
axelvento axelvento 4 월 전
bouncer$ ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

https://immunitybio.com/immunitybio-presents-positive-long-term-overall-survival-data-in-non-small-cell-lung-cancer-patients-and-announces-registrational-intent-phase-3-trials-with-anktiva-and-checkpoint-immunotherapy/
👍️0
Monksdream Monksdream 4 월 전
IBRX under $4
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 4 월 전
Down and down, is approval for other cancer expected in June dead?
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 5 월 전
Why did IBRX tank so badly in mid August?
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 5 월 전
IBRX at $4

Wow. Where is the pancreatic cancer approval expected in June?

👍️0
Monksdream Monksdream 5 월 전
IBRX under $6
👍️0
Monksdream Monksdream 6 월 전
IBRX under $10
👍️0
jgrabar jgrabar 6 월 전
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ImmunityBio, Inc. (IBRX)
See https://grabarlaw.com/the-latest/immunitybio-shareholder-investigation/
👍️0
tw0122 tw0122 6 월 전
09:45 AM EDT, 06/20/2024 (MT Newswires) -- ImmunityBio (IBRX) said Thursday that it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US receiving the initial commercial doses.

The US Food and Drug Administration approved Anktiva in April to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with or without papillary tumors, according to ImmunityBio.
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 6 월 전
Any thoughts on how much revenue FDA approval will bring?
👍️0
wrk_SATX wrk_SATX 7 월 전
Still +54M shares short and time is ticking. 80% inside ownership with a small float.
👍️0
saigai saigai 8 월 전
up and down.. no problem.. ima staying put
👍️0
saigai saigai 8 월 전
we know there is a very large short position here.. i think that since the earnings post yesterday and the reaction to it that there is now very little reason to stay short,,lets see that spike
👍️0
carldfw carldfw 8 월 전
Pancreatic Cancer next!!
I like Oncolytics on that list
👍️0
Tahoe2468 Tahoe2468 8 월 전
7. ImmunityBio Inc (NASDAQ:IBRX)
Float Shorted: 40.37%

With over 53 million of its shares shorted, ImmunityBio Inc’s (NASDAQ:IBRX) short interest stands at 40.37% as of April 8.
👍️0
jondoeuk jondoeuk 8 월 전
From Jan 19, 2023: ''ImmunityBio also announced that it held two productive Type B meetings with the FDA in December. The first was to present the recent data and obtain guidance toward a registration pathway in metastatic pancreatic cancer.'' https://www.businesswire.com/news/home/20230119005337/en/ImmunityBio-Announces-Presentation-at-ASCO-GI-2023-of-Fully-Enrolled-Trial-in-Third-Line-and-Greater-Pancreatic-Cancer-and-Update-on-FDA-Type-B-Meetings-Regarding-Paths-to-Registration

What happened?
👍️0
jondoeuk jondoeuk 8 월 전
Nothing listed in the pipeline.
👍️0
Tahoe2468 Tahoe2468 8 월 전
Pancreatic Cancer next!! WOW!!

https://www.prnewswire.com/news-releases/biotechs-role-in-addressing-the-pancreatic-cancer-emergency-302089052.html
👍️0
TrendTrade2016 TrendTrade2016 8 월 전
IBRX monster bio on the weekly break out
👍️0
MiamiGent MiamiGent 8 월 전
IBRX Friday Close $7.35+$2.24 (+43.84%)

This morning Pre-Mkt
Bid x Size
$8.13 x 2
Ask x Size
$8.20 x 212
Volume
862,349
90 Day Avg. Vol.
4,851,152

Bona fide squeeze underway. Millions of shares short are trapped.
👍️ 1
carldfw carldfw 8 월 전
Pancreatic will be even better!!In January 2023, ImmunityBio announced that it held two meetings with the FDA in December 2022 to present data and get guidance on a registration pathway for metastatic
pancreatic cancer
. The company's combination immunotherapy
, Nant Cancer Vaccine, has shown potential effectiveness in pancreatic cancer, more than doubling median overall survival (OS) compared to historical OS.
👍️0
martind18 martind18 8 월 전
That’s because IHUB is for pump and dumps.
👍️ 2
Atom Smasher Atom Smasher 8 월 전
Good ole ihub. We have a REAL company here with a remarkable game changing cancer drug whose stock price will not only explode but retain it's stock price and no one here is even talking about it. As per my experience here several years ago.......everyone here is only interested in shells and scam companies. What a shame. That's fine. I'll be making bank. Join me if you want.......or don't. I'm not selling till it's somewhere above 40
👍️ 2
Monksdream Monksdream 8 월 전
This a simple bar/volume with 60-minute intervals


The stock is actually trading counter to a recent bearish trend for most tickers according my bit of DD from the Barchart website that would be considered med tech companies
This a link for the sector that is made up 459 tickers
https://www.barchart.com/stocks/quotes/IBRX/competitors?quoteSectors=-MEBI&viewName=main&orderBy=weightedAlpha&orderDir=desc

I have a free membership so I can use the flipcharts function for the past six months of price discovery
One can observe from the sector graph at the top of the page the best time to buy any old med stock was last November
The best time to sell was at the peak last March which isn’t that long ago
I can observe the same recurring pattern in the more than 200 tickers I flipped through
👍️0
Atom Smasher Atom Smasher 8 월 전
https://www.barchart.com/stocks/quotes/IBRX/opinion
👍️0
Monksdream Monksdream 8 월 전
IBRX in the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️ 1
axelvento axelvento 8 월 전
https://twitter.com/YahooFinance/status/1782859110771278268
👍️ 1
Pt3 Pt3 8 월 전
Welcome
👍️0
martind18 martind18 8 월 전
FDA approval!

https://www.investorsobserver.com/news/qm-news/8088196297645818
👍️0
axelvento axelvento 9 월 전
The FDA has accepted the BLA resubmission and will now review the therapy. It has set a Prescription Drug User Fee Act (PDUFA) date of 23 April 2024.
👍️0
Monksdream Monksdream 10 월 전
IBRX chart
👍️0
Spideyboy Spideyboy 10 월 전
Just curious, having read this article from June 2022, what makes us think that they will get approval for Antikva.

My concern just stems from the bottom of the article stating.

"Other drugs are in late-stage trials in combination with BCG for the same patient population, including AstraZeneca’s Imfinzi (durvalumab) and Sesen Bio’s Vicinium (oportuzumab monatox). The FDA previously rejected Sesen Bio’s BLA for the treatment of BCG-unresponsive patients, citing multiple issues, including a lack of randomised data comparing Vicinium with an investigator’s choice of intravesical chemotherapy."
https://www.pharmaceutical-technology.com/analyst-comment/immunitybio-first-marketed-drug/?cf-view

There is no comparator in the Antikva trial with any intravesical chemotherapy either, or against anything for that matter. As it's open-label single arm trial, with only Antikva being used. Will this be enough for FDA approval?

I know the prior CRL didn't mention anything about this, but that doesn't mean it isn't a potential issue?

Looking to be convinced wrong on the above :)
👍️0
Monksdream Monksdream 10 월 전
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0

최근 히스토리

Delayed Upgrade Clock